IDEAYA Biosciences Inc. Common Stock (IDYA)

About IDYA

IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with c…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

145

Website

www.ideayabio.com/

Fundamentals

1-day range

$37.84$39.3

Market cap

$3.50B

P/E (trailing)

—

P/E (forward)

-9.46

EPS (trailing)

$-1.94

Dividend yield

—

Beta

-0.04

Avg. volume

1.07M

Forecasts

13 analyst ratings

IDEAYA Biosciences Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• IDYA

  IDEAYA Biosciences Inc. Common Stock

  $40.13

  ▼ 3.93%
  Market cap $3.50BP/E —
  $23.23$42.68
• ALMS

  Alumis Inc. Common Stock

  $22.38

  ▼ 3.58%
  Market cap $3.54BP/E —
  $3.76$31.35
• TLX

  Telix Pharmaceuticals Limited American Depositary Shares

  $11.28

  ▼ 0.84%
  Market cap $3.60BP/E —
  $6.28$12.5
• ELVN

  Enliven Therapeutics Inc. Common Stock

  $57.82

  ▼ 4.43%
  Market cap $3.67BP/E —
  $14.79$62.32
• ARQT

  Arcutis Biotherapeutics Inc. Common Stock

  $23.78

  ▼ 4.38%
  Market cap $3.31BP/E 113.86
  $15.1$31.77
• GPCR

  Structure Therapeutics Inc. American Depositary Shares

  $47.38

  ▼ 3.74%
  Market cap $3.74BP/E —
  $18.26$94.9
• NAMS

  NewAmsterdam Pharma Company N.V. Ordinary Shares

  $25.9

  ▼ 3.32%
  Market cap $3.23BP/E —
  $23.05$42.21

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• IDEAYA Biosciences Enters Clinical Collaboration With Roche's Genentech To Evaluate The Efficacy And Safety Of IDE892, Its Investigational MTA-Cooperative PRMT5 Inhibitor, In Combination With GDC-7035, Genentech's KRAS G12D Inhibitor, In Patients With Pancreatic Ductal Adenocarcinoma
  Benzinga · 8/19/2026
• IDEAYA Biosciences (NASDAQ:IDYA) Displays Perfect Technical Strength and Breakout Setup
  ChartMill · 8/10/2026
• Truist Securities Maintains Buy on IDEAYA Biosciences, Lowers Price Target to $59
  Benzinga · 8/5/2026
• Wedbush Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $60
  Benzinga · 8/5/2026
• IDEAYA Biosciences Q2 EPS $(1.22) Misses $(1.09) Estimate, Sales $8.857M Beat $5.015M Estimate
  Benzinga · 8/4/2026

• Ruiz Briseno Andres · July 7, 2026 · Option Exercise

  9.6K @ $12.86
• Ruiz Briseno Andres · July 7, 2026 · Sale

  9.6K @ $40.01
• MACKEY CATHERINE J · June 16, 2026 · Grant

  20.0K
• Stein Jeffrey · June 16, 2026 · Grant

  20.0K
• ROSEN TERRY J · June 16, 2026 · Grant

  20.0K
• Wendy L. Yarno · June 16, 2026 · Grant

  20.0K
• Stein Jeffrey · March 2, 2026 · Buy

  50.0K @ $32.96

Institutional Ownership

March 31, 2026

Total shares held

95.30M

Total value held

$3.13B

Institutional holders

249